Last reviewed · How we verify
L19TNF
At a glance
| Generic name | L19TNF |
|---|---|
| Also known as | onfekafusp alpha, onfekafusp alfa |
| Sponsor | Philogen S.p.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (PHASE2)
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (PHASE2)
- L19IL2/TNF in Patients With Basal Cell Carcinoma (PHASE2)
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (PHASE3)
- A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma (PHASE2)
- Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma (PHASE2)
- A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (PHASE2)
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19TNF CI brief — competitive landscape report
- L19TNF updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI